The US compassionate experience with thymoglobulin for the treatment of resistant acute rejection

Daoud, A. Jamal

doi:10.1016/s0041-1345(97)90014-2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Rejection: Ratg Versus Equine Anti-thymocyte Globulin1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[67][68][69][70][71][72] Daoud et al reported results of compassionate use rATG for 26 patients with solid organ transplants suffering resistant rejection after treatment with high dose steroids, eATG, OKT3, plasmapheresis, irradiation among other therapies. 73 rATG reversed the rejection in 85% of the patients with mean creatinine falling from 4.7 mg/dl pre-treatment to 1.7 mg/dl 3 months post-treatment.…”

Section: Rejection: Ratg Versus Equine Anti-thymocyte Globulinmentioning

confidence: 93%

Rabbit Anti-Thymocyte Globulin: Evidence for Clinical Benefit in High Immunological Risk Kidney Transplantation

Martin

Wadei

Gonwa

2011

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Rabbit anti-thymocyte globulin is used worldwide to treat and prevent rejection in kidney transplantation. Multiple mechanisms of action of this polyclonal preparation are responsible for its success. Studies have supported clinical benefits of rabbit anti-thymocyte globulin in high immunological risk kidney transplant recipients when used as an induction agent at the time of transplant and for treatment of rejection when compared to other antibody therapy. The evidence of this clinical benefit will be reviewed in addition to examining the dosing and safety profile of rabbit anti-thymocyte globulin.

show abstract